The Kislinger Laboratory is located at the Princess Margaret Cancer Research Tower of the Princess Margaret Cancer Centre, the largest oncology treatment and research facility in Canada. The major goal of our lab is to apply proteomics technologies to cancer and cardiovascular research. Our research interests include technology development, using the latest generation of mass spectrometry instrumentation, basic cell biology and translational cancer research.
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.
J Proteome Res. 2012 Apr 6;11(4):2386-96
J Interferon Cytokine Res. 2012 Mar;32(3):127-37
The replication-independent histone H3-H4 chaperones HIR, ASF1, and RTT106 co-operate to maintain promoter fidelity.
J Biol Chem. 2012 Jan 13;287(3):1709-18
Translational analysis of mouse and human placental protein and mRNA reveals distinct molecular pathologies in human preeclampsia.
Mol Cell Proteomics. 2011 Dec;10(12):M111.012526
Choice of biological source material supersedes oxidative stress in its influence on DJ-1 in vivo interactions with Hsp90.
J Proteome Res. 2011 Oct 7;10(10):4388-404
Use of colloidal silica-beads for the isolation of cell-surface proteins for mass spectrometry-based proteomics.
Methods Mol Biol. 2011;748:227-41
A cost-benefit analysis of multidimensional fractionation of affinity purification-mass spectrometry samples.
Proteomics. 2011 Jul;11(13):2603-12
In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
J Proteome Res. 2011 May 6;10(5):2286-99
Identification of novel ryanodine receptor 1 (RyR1) protein interaction with calcium homeostasis endoplasmic reticulum protein (CHERP).
J Biol Chem. 2011 May 13;286(19):17060-8
Senior Scientist, Princess Margaret Cancer Centre